Cosela mak­er's ear­ly em­ploy­ees aim to repli­cate 'blue­print' at a new biotech — with an old G1 as­set

Three of the ear­li­est em­ploy­ees at G1 Ther­a­peu­tics want to re­peat the blue­print they laid at se­cur­ing ap­proval for CDK4/6 in­hibitor Cosela by tak­ing a dif­fer­ent CDK fam­i­ly mem­ber through the clin­ic, and at a new com­pa­ny.

In­cy­clix Bio — launched in 2020 un­der for­mer name Arc Ther­a­peu­tics with an ex­clu­sive li­cense to G1’s CDK2 in­hibitor — has picked up $30 mil­lion in Se­ries B funds to take its as­set in­to the clin­ic in the fourth quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER